Gastroretentive Drug Delivery Systems Patent Landscape Analysis Report 2026 Edition

Gastroretentive Drug Delivery Systems Market Size, Growth Trends, and Industry Outlook

Gastroretentive systems extend the time a dosage form stays in the stomach, which gives drugs with a narrow absorption window in the upper small intestine more time to dissolve and cross the gut wall. Interest comes from formulators who handle weakly basic drugs, locally acting agents and compounds that degrade in the colon. Demand is also shaped by the shift from daily tablets to weekly and monthly oral regimens, where stomach residence for days replaces a short gastric transit of one to four hours.

Market growth is driven by the pipeline of drugs that need prolonged gastric residence and by the commercial track record of gastric retentive tablets for metformin and gabapentin. Around 830 million people live with diabetes worldwide according to the World Health Organization, and metformin remains first-line therapy for most of them.

North America holds the largest share because the first FDA approvals for gastric retentive tablets came from United States companies, and the region carries high diabetes and neuropathic pain prescribing volumes. The 2025 Lancet Psychiatry report on a once-weekly risperidone capsule shows that stomach-resident devices can sustain therapeutic levels for seven days, which opens psychiatric, contraceptive and infectious disease uses that a standard tablet cannot serve. Asia Pacific is expanding quickly as Chinese and Indian formulators file floating and swelling tablets for generic extended-release drugs, lifting volume and sharpening price competition.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Gastroretentive Drug Delivery Systems Patent Filing Trends and Innovation Activity

Patent filing in gastroretentive drug delivery systems has moved from simple floating tablets toward engineered devices and drug-polymer composites. Early families from the 1990s and 2000s covered effervescent floating matrices and swelling hydrogels. Recent filings address folded frames, shape-memory polymers and ingestible depots designed for residence of days.

The dataset holds about 3,400 patent families, with filing peaks between 2008 and 2013 around swelling tablets and a second rise after 2018 around expandable devices. Chinese universities and generic firms contribute a large share of the volume, while United States filers hold the more heavily cited device claims.

Rising demand for weekly oral dosing and for absorption-window drugs shows up in the patent record as sustained growth in expandable frame and depot capsule families.

Scope of the Gastroretentive Drug Delivery Systems Patent Landscape Analysis Report

This report covers granted patents and published applications on dosage forms and devices that prolong gastric residence of an active ingredient. It includes floating, swelling, expandable, mucoadhesive, high-density and magnetic approaches, together with the polymers, gas-generating agents and delivery capsules that support them.

Coverage spans formulation compositions, device geometry, manufacturing methods and methods of treatment tied to gastric retention. Entries are consolidated by patent family and tracked by assignee, priority year, jurisdiction and technology cluster.

The assignee analysis includes pharmaceutical manufacturers, specialty delivery companies, generic firms, universities and research institutes that hold gastroretentive families.

Global Gastroretentive Drug Delivery Systems Patent Landscape Analysis

Gastroretentive Drug Delivery Systems Patent Filing Trend Analysis

Filing volume for gastroretentive drug delivery systems grew at an estimated annual rate of about 6% between 2020 and 2024. Growth came from Chinese academic output on floating and mucoadhesive carriers and from United States filings on expandable devices that hold drugs for a week.

Grants in 2025 reached roughly 285 patents, a modest share of the more than 1,420 patents linked to the primary jurisdiction. Examination of polymer-matrix claims is slower because prior art on floating tablets is dense, so applicants increasingly move claims toward device geometry, release linkers and indication-specific dosing.

Leading Companies and Assignee Analysis in the Gastroretentive Drug Delivery Systems Patent Landscape

Geographic Analysis of Gastroretentive Drug Delivery Systems Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

China leads by filing volume, driven by university research on floating and mucoadhesive carriers and by domestic generic developers. The United States follows with the commercially validated platforms and the device-focused families. India ranks third, reflecting formulation work by generic manufacturers on extended-release tablets with gastric retention.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Gastroretentive Drug Delivery Systems Technology Segmentation and Innovation Areas

The technology segments covered in this report include:

• Floating and effervescent matrix systems
• Swelling and expandable polymer frames
• Mucoadhesive and bioadhesive gastric carriers
• High-density and magnetic retention systems
• Ingestible depot capsules for weekly dosing

Among these, floating and effervescent matrix systems account for the largest share of patent families because of their low manufacturing cost and long record in extended-release tablets.

Competitive Landscape and Emerging Trends in the Gastroretentive Drug Delivery Systems Market

Competition combines legacy platform holders, generic manufacturers and device-focused entrants. Sun Pharmaceutical Industries and Assertio own formulation-level claims that anchor commercial tablets, while Lyndra Therapeutics and Massachusetts Institute of Technology hold device claims behind weekly oral depots. Licensing from academic groups to spinouts is a recurring route to market.

Companies are focusing on:

• Floating matrix tablets with gas-generating agents
• Shape-memory and star-shaped expandable frames
• Enteric elastomer linkers for timed disintegration
• Mucoadhesive polymers for gastric mucosa binding
• Raft-forming alginate liquids for local action
• Weekly oral depots for antipsychotics and contraceptives
• Fed-state dosing regimens for narrow absorption window drugs

Emerging innovation themes include once-weekly oral antipsychotic capsules, ingestible depots for malaria prophylaxis, and expandable frames loaded with antiretrovirals. Magnetically guided retention and three-dimensional printed floating tablets are gaining early filings. Computational models of gastric emptying are also being claimed to personalise dose design.

Strategic Insights from the Gastroretentive Drug Delivery Systems Patent Landscape

The competitive position in gastroretentive drug delivery systems depends on device geometry claims, polymer grade know-how and clinical evidence of residence time. Established tablet platforms are maturing as core families expire, which opens generic entry. New value is shifting toward weekly oral depots and combination products.

Technology segments, assignee positions and jurisdictional trends in gastroretentive drug delivery systems are analysed in nine areas, and the report provides actionable intelligence supporting:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Gastroretentive Drug Delivery Systems Patent Landscape Analysis

The study searches patent databases at the USPTO, the European Patent Office, the China National Intellectual Property Administration, the Indian Patent Office, the Japan Patent Office and WIPO PATENTSCOPE. Records cover publications from 2000 to 2025.

Queries combine keywords on gastric retention, floating, swelling, mucoadhesion and expandable devices with CPC classes A61K 9/0065, A61K 9/0004 and A61K 9/20, plus IPC A61K 9/22 and A61J 3/07. Results are screened manually, deduplicated and consolidated at patent family level before assignee normalisation.

The market side draws on FDA and EMA approval records, company filings, clinical trial registries and peer-reviewed literature. Patent trends are cross-checked against product launches and licensing disclosures.

Related Reports

Controlled Release Drug Delivery Market

Long-Acting Drug Delivery Technologies and Services Market

Microneedles for Drug Delivery Patent Landscape Analysis